Cargando…

Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib

Patients with non‐small cell lung cancer (NSCLC) and uncommon epidermal growth factor receptor (EGFR) mutation are characterized by high heterogeneity, and globally considered to have a worse prognosis than patients with the two common mutations; exon 19 deletion, and exon 21 L858R. Nevertheless, so...

Descripción completa

Detalles Bibliográficos
Autores principales:	Longo, Vito, Catino, Annamaria, Montrone, Michele, Pizzutilo, Pamela, Pesola, Francesco, Marech, Ilaria, Capone, Iolanda, Prelaj, Arsela, Galetta, Domenico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258364/ https://www.ncbi.nlm.nih.gov/pubmed/34008923 http://dx.doi.org/10.1111/1759-7714.13953

Ejemplares similares

What Are the Biomarkers for Immunotherapy in SCLC?
por: Longo, Vito, et al.
Publicado: (2021)

Esophageal Stricture Caused by ALK-Positive NSCLC Esophageal Metastasis Resolved After a Few Days of Lorlatinib Therapy Without Stent Placement
por: Longo, Vito, et al.
Publicado: (2020)

Prognostic factors for survival in extensive‐stage small cell lung cancer: An Italian real‐world retrospective analysis of 244 patients treated over the last decade
por: Longo, Vito, et al.
Publicado: (2022)

Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review
por: Montrone, Michele, et al.
Publicado: (2023)

Gender Differences and Immunotherapy Outcome in Advanced Lung Cancer
por: Vavalà, Tiziana, et al.
Publicado: (2021)

Controversial role of mast cells in NSCLC tumor progression and angiogenesis
por: Longo, Vito, et al.
Publicado: (2022)

Safety evaluation of immune checkpoint inhibitors combined with chemotherapy for the treatment of small cell lung cancer: A meta‐analysis of randomized controlled trials
por: Longo, Vito, et al.
Publicado: (2023)

Favourable outcome of coronavirus disease 2019 in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving alectinib
por: Montrone, Michele, et al.
Publicado: (2020)

Impact of tobacco control interventions on smoking initiation, cessation, and prevalence: a systematic review
por: Bafunno, Daniela, et al.
Publicado: (2020)

Incidence of Infections and Predictors of Mortality During Checkpoint Inhibitor Immunotherapy in Patients With Advanced Lung Cancer: A Retrospective Cohort Study
por: Bavaro, Davide Fiore, et al.
Publicado: (2021)

Informative Power Evaluation of Clinical Parameters to Predict Initial Therapeutic Response in Patients with Advanced Pleural Mesothelioma: A Machine Learning Approach
por: Massafra, Raffaella, et al.
Publicado: (2022)

MCSE Core Elective Exams in a Nutshell: Covers exams 70-270, 70-297, and 70-298
por: Bhardwaj, Pawan, et al.
Publicado: (2006)

A CT-based transfer learning approach to predict NSCLC recurrence: The added-value of peritumoral region
por: Bove, Samantha, et al.
Publicado: (2023)

Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report
por: Catino, Annamaria, et al.
Publicado: (2022)

FP06.04 Psychological Distress in Outpatients with Lymphoma, Lung and Breast Cancer during COVID-19 pandemic
por: Catino, A., et al.
Publicado: (2021)

Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low‐dose afatinib: A case report
por: Iida, Yuko, et al.
Publicado: (2019)

861. Health Disparities in HIV and Pregnancy
por: Abbas, Anum, et al.
Publicado: (2018)

Fungal Planet description sheets: 785–867
por: Crous, P.W., et al.
Publicado: (2018)

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

EGFR-L861Q突变对TKI类药物敏感性预测分析及病例报道
Publicado: (2015)

Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review
por: Lin, Ruiting, et al.
Publicado: (2021)

Predominance of the Rare EGFR Mutation p.L861Q in Tunisian Patients with Non-Small Cell Lung Carcinoma
por: Abdelmaksoud-Dammak, Rania, et al.
Publicado: (2022)

297. Lactobacillus: Friend or Foe
por: Nwanyanwu, Chiemeziem, et al.
Publicado: (2020)

Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?
por: Iwamoto, Natsuhiko, et al.
Publicado: (2022)

KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy
por: Rosamaria, Pinto, et al.
Publicado: (2019)

Breath Analysis: Comparison among Methodological Approaches for Breath Sampling
por: Di Gilio, Alessia, et al.
Publicado: (2020)

An elderly advanced non-small cell lung cancer patient harboring rare epidermal growth factor receptor mutations L861R benefited from afatinib: A case report
por: Qu, Fanjie, et al.
Publicado: (2021)

Fundus Examination of 23,861 Newborns by Digital Imaging in Ningbo
por: Liu, Delin, et al.
Publicado: (2021)

Health Tract, No. 297: Brain Work
Publicado: (1867)

Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report
por: Zhang, Yao, et al.
Publicado: (2021)

785. Identifying Opportunities to Improve Adherence to Sepsis Care Guidelines Compliance
por: Balankura, Tonnam, et al.
Publicado: (2019)

Mechanism of use-dependent Kv2 channel inhibition by RY785
por: Marquis, Matthew James, et al.
Publicado: (2022)

Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
por: Watanabe, Satoshi, et al.
Publicado: (2014)

Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation
por: Chen, Yen-Ju, et al.
Publicado: (2019)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
por: Jiang, Yingying, et al.
Publicado: (2023)

Neoadjuvant Chemotherapy in Neuroendocrine Bladder Cancer: A Case Report
por: Prelaj, Arsela, et al.
Publicado: (2016)

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
por: Yamamoto, Nobuyuki, et al.
Publicado: (2019)

Evaluation of Treatment Efficacy of Tyrosine Kinase Inhibitors in Rare Single EGFR Exon 21 L861Q Mutation: Single Center Experience
por: Gürsoy, Pınar, et al.
Publicado: (2022)

785 Assessing The Kinematics Of Virtual Reality Gaming As Physical Therapy In Burn Patients
por: Qiu, Cecil S, et al.
Publicado: (2022)

785. Bacterial Co-infection and Empirical Antibiotic Therapy in Patients with COVID-19
por: Lee, Jiyoung, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vqnln7o3o24nbfft41t18bjtah